HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
2-((2,3-Dimethylphenyl)amino)-benzoesäure
Mefenamic · Mefanamic acid · MEFENAMATE · Ponstel · LFR · INTL · Ponstan · ac.mefenamico
Identifikatoren & physikalische Daten
| CAS No. | 61-68-7 |
|---|---|
| Summenformel | C15H15NO2 |
| Durchschnittliche Molmasse | 241,28 g/mol |
| Monoisotopische Masse | 241,11027872 g/mol |
| SMILES | Cc1cccc(Nc2ccccc2C(=O)O)c1C |
| InChIKey | HYYBABOKPJLUIN-UHFFFAOYSA-N |
| PubChem CID | 4044 |
| ChEMBL | CHEMBL686 |
| ChEBI | CHEBI:6717 |
| EC No. | 200-513-1 |
| DTXSID | DTXSID5023243 |
| Lokaler Name | 2-((2,3-Dimethylphenyl)amino)-benzoesäure |
Chemische & physikalische Eigenschaften
| XLogP | 5,1 |
|---|---|
| Polarare Oberfläche (TPSA) | 49,3 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 3 |
| Schwere Atome | 18 |
| Formalladung | 0 |
| Komplexität | 292 |
| Arzneimittel | DEA NFLIS-Drug Category -> AnalgesicsPharmaceuticals -> Used in SwitzerlandPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> NSAIDs |
| LogP (Verteilungskoeffizient) | 4.24.38 |
| Color/Form | CRYSTALSWHITE TO OFF-WHITE, CRYSTALLINE POWDER |
| Löslichkeit | WHITE POWDERSOLUBILITY IN WATER: GREATER THAN 5 G/100 ML /SODIUM SALT/IN WATER @ PH 7.1: 0.0041 G/100 ML @ 25 °C, 0.008 G/100 ML @ 37 °CSOL IN SOLN OF ALKALI HYDROXIDESSPARINGLY SOL IN ETHER, CHLOROFORMSLIGHTLY SOL IN ETHANOL1 G SOL IN 26 ML DIMETHYLFORMAMIDE & 220 ML ALCOHOL1.37e-02 g/L>36.2 [ug/mL] (The mean of the results at pH 7.4)Practically insoluble in water, slightly soluble in ethanol (96 per cent) and in methylene chloride. It dissolves in dilute solutions of alkali hydroxidesIt is soluble in acetone, chloroform, dichloromethane, methanol. Insoluble in water. |
| Human Drugs | Breast FeedingLactationMilk, HumanAnalgesic AgentsAntii-nflammatory Agents, NonsteroidalFDA approved drugs -> Active ingredientPharmaceuticals |
| Schmelzpunkt | 230-231 °CDECARBOXYLATES @ TEMP ABOVE ITS MELTING POINT (@ 300 °C, 100% IS DECARBOXYLATED IN 3 MIN)230 - 231 °C230 °C |
| Physical Description | Solid |
| Stability/Shelf Life | DARKENS ON PROLONGED EXPOSURE TO LIGHT, IS STABLE @ 25 DEG, 37 DEG, & 45 °C. |
| Dissociation Constants | 4.24.5PKA 4.2 |
| Collision Cross Section | 152.3 Ų [M]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID5023243]150.5 Ų [M+H]+ [CCS Type: TW]153.3 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]153.25 Ų [M+H]+ |
| Other Experimental Properties | EFFERVESCENCE |
| Siedepunkt | 384.06°C (rough estimate) |
| Dichte | 1.0944 (rough estimate) |
| Brechungsindex | 1.5200 (estimate) |
| Lagerbedingungen | 2-8°C |
| pKa (Säurekonstante) | 4.2(at 25℃) |
| Aggregatzustand | Solid |
| Farbe | White to Pale Yellow |
| Merck | 14,5798 |
| Hauptanwendungen | forensics and toxicologypharmaceutical (small molecule)veterinary |
| InChI | 1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18) |
| InChIKey | HYYBABOKPJLUIN-UHFFFAOYSA-N |
| SMILES | Cc1cccc(Nc2ccccc2C(O)=O)c1C |
| LogP (Verteilungskoeffizient) | 5.120 |
| CAS Datenbank | 61-68-7(CAS DataBase Reference) |
| NIST chemische Informationen | Mefenamic acid(61-68-7) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 0.8% (1 of 126) of reports.WarningH302 (99.2%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 126 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Danger |
|---|---|
| Regulatorische Informationen | Mefenamic acid: Does not have an individual approval but may be used under an appropriate group standard |
| Weitere Sicherheitsinformationen | IMAP assessments - Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-: Environment tier I assessment |
| Hazard Classes and Categories | Acute Tox. 4 (99.2%)Acute toxicity (Oral) - Category 4 |
| Wechselwirkungen | ...WARFARIN CAN BE DISPLACED FROM PLASMA PROTEIN BY MEFENAMIC ACID...INCR IN FREE WARFARIN CAN RANGE FROM 66-400% WITH CORRESPONDING INCR IN ANTICOAGULANT ACTION. BECAUSE OF DOSAGES INVOLVED, INTERACTIONS ARE MORE LIKELY TO BE IMPORTANT IN PT TREATED WITH WARFARIN THAN IN WORKERS WHO USE IT AS PESTICIDE...EFFECTS OF ORAL ANTICOAGULANT AGENTS ARE ENHANCED. |
| Hepatotoxicity | In prospective studies less than 5% of patients taking mefenamic acid experienced transient serum aminotransferase elevations. The abnormalities usually resolved even while continuing the drug and without dose modification. Marked aminotransferase elevations (>3 fold elevated) occurred in |
| Human Toxicity Excerpts | ...DIARRHEA IS COMMON & OFTEN SEVERE, & GI ULCERATION & BLEEDING HAVE BEEN REPORTED. EXACERBATION OF ASTHMA, AUTOIMMUNE HEMOLYTIC ANEMIA, ALBUMINURIA, & SLIGHT ELEVATION OF BLOOD UREA NITROGEN MAY OCCUR. AGRANULOCYTOSIS, THROMBOCYTOPENIC PURPURA, MEGALOBLASTIC ANEMIA, & PANCYTOPENIA HAVE BEEN REPORTED....UNDESIRED EFFECTS INCL DROWSINESS, NAUSEA, DIZZINESS, NERVOUSNESS, & HEADACHE.MINOR REACTIONS INCL...VOMITING, URTICARIA, RASH, EOSINOPHILIA, BLURRED VISION, INSOMNIA, & PERSPIRATION. RARELY, PALPITATIONS, FACIAL EDEMA, DYSPNEA, EYE PAIN, EAR PAIN, DYSURIA, HEMATURIA, REVERSIBLE LOSS OF COLOR VISION, & INCR INSULIN NEED IN DIABETIC PT. MILD RENAL & HEPATIC TOXICITY HAVE ALSO BEEN REPORTED. |
Anwendungen & Verwendung
Verwenden
Mefenamic acid is used for the same indications as flufenamic acid. Synonyms for this drug are parkemed, ponstan, ponstel, and others.